CAR T-Cell Therapy for Relapsed/Refractory CLL
2 Tampilan
• 07/14/23
0
0
Menanamkan
administrator
Pelanggan
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru